NASDAQ:HRTX - Heron Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.06 -0.21 (-1.15 %)
(As of 05/19/2019 11:24 AM ET)
Previous Close$18.06
Today's Range$18.00 - $18.55
52-Week Range$16.20 - $42.90
Volume948,833 shs
Average Volume1.92 million shs
Market Capitalization$1.43 billion
P/E RatioN/A
Dividend YieldN/A
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HRTX



Sales & Book Value

Annual Sales$77.47 million
Book Value$4.19 per share


Net Income$-178,840,000.00
Net Margins-194.43%


Market Cap$1.43 billion
Next Earnings Date8/14/2019 (Estimated)

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) posted its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.30. The biotechnology company had revenue of $31.60 million for the quarter, compared to the consensus estimate of $28.04 million. Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. Heron Therapeutics's quarterly revenue was up 172.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.09) EPS. View Heron Therapeutics' Earnings History.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Heron Therapeutics.

What guidance has Heron Therapeutics issued on next quarter's earnings?

Heron Therapeutics issued an update on its FY 2019 earnings guidance on Friday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $115-120 million, compared to the consensus revenue estimate of $174.08 million.

What price target have analysts set for HRTX?

9 Wall Street analysts have issued 1-year target prices for Heron Therapeutics' stock. Their predictions range from $38.00 to $80.00. On average, they expect Heron Therapeutics' stock price to reach $53.1111 in the next year. This suggests a possible upside of 194.1% from the stock's current price. View Analyst Price Targets for Heron Therapeutics.

What is the consensus analysts' recommendation for Heron Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. Cowen Inc analysts commented, ": Post 1Q19, we are reiterating our Overweight rating and $18 PT on CHMA. We believe the stock continues to trade at a significant discount to its potential intrinsic value. We believe the risk-reward going into Phase 3 data for Mycapssa (oral octreotide) for the treatment of acromegaly, to be released in 3Q19, remains positive. As the company advances Mycapssa toward approval, we expect data readouts, approvals, and upward earnings revisions to drive CHMA’s stock higher." (5/9/2019)
  • 2. Northland Securities analysts commented, "We anticipate the Company will submit a briefing package to the FDA and request a ‘Type A’ meeting to clarify issues cited in the Complete Response Letter (CRL) received on April 30, 2019 relating to the NDA for HTX-011 (bupivacaine ER, plus meloxicam ER) for the treatment of post-operative pain management. The CRL requested additional Controls (CMC) and non-clinical information deemed necessary for HTX-011’s approval. We anticipate a Type A meeting will be held late-June/early-July, with minutes available within 30 days of its occurrence. We anticipate the minutes will clarify a path forward for resubmission of the NDA for HTX-011." (5/9/2019)
  • 3. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/9/2019)
  • 4. Stifel Nicolaus analysts commented, "We are certainly disappointed in the CRL for HTX-011, there is no doubt about that, but we would be buying today’s weakness as we continue to believe HTX-011 will be approved. The FDA flagged CMC and non-clinical issues and it is a bit hard to know, at this time, exactly when the company will be able to re-file its NDA until HRTX meets with the FDA. With that said, we remain confident in HTX-011’s approvability given its robust Phase 2/3 dataset, opioid sparing capability and the fact the FDA is not requiring any additional clinical work, which we view as a good sign. With the stock trading around ~$18, we think this is a significant buying opportunity for long-term investors given HTX-011’s product profile and the size of the commercial opportunity. We lower our target price to $38 to reflect a delayed HTX-011 approval and launch. Reiterate Buy." (5/1/2019)
  • 5. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and expect upward earnings revisions, along with an approval of HTX-011, to drive HRTX shares higher. We expect upside to come from Cinvanti and HTX-011. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $50." (12/31/2018)

Has Heron Therapeutics been receiving favorable news coverage?

News articles about HRTX stock have trended positive on Sunday, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Heron Therapeutics earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Cara Therapeutics (CARA), Micron Technology (MU), Seattle Genetics (SGEN), bluebird bio (BLUE), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Gilead Sciences (GILD), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE) and ImmunoGen (IMGN).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:
  • Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
  • Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
  • Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Sean T. Ristine, VP of HR (Age 49)

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.70%), Tang Capital Management LLC (7.25%), Janus Henderson Group PLC (6.65%), Wellington Management Group LLP (6.50%), BlackRock Inc. (6.14%) and ArrowMark Colorado Holdings LLC (3.37%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View Institutional Ownership Trends for Heron Therapeutics.

Which institutional investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, FIL Ltd, Morgan Stanley, Janus Henderson Group PLC, Tang Capital Management LLC, Wells Fargo & Company MN, BlackRock Inc. and Bank of Montreal Can. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart, Kevin C Tang, Kimberly Manhard, Robert Hoffman and Robert Rosen. View Insider Buying and Selling for Heron Therapeutics.

Which institutional investors are buying Heron Therapeutics stock?

HRTX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Wellington Management Group LLP, WS Management Lllp, ArrowMark Colorado Holdings LLC, FMR LLC, Rosenblum Silverman Sutton S F Inc. CA, Oak Ridge Investments LLC and Candriam Luxembourg S.C.A.. Company insiders that have bought Heron Therapeutics stock in the last two years include Kevin C Tang and Waage Christian. View Insider Buying and Selling for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $18.06.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.43 billion and generates $77.47 million in revenue each year. The biotechnology company earns $-178,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

MarketBeat Community Rating for Heron Therapeutics (NASDAQ HRTX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  533 (Vote Outperform)
Underperform Votes:  339 (Vote Underperform)
Total Votes:  872
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel